Juno Therapeutics (JUNO) is the ‘Chart of the Day’

NEW YORK (TheStreet) --Shares of Juno Therapeutics Inc. (JUNO) are higher by 3.13% to $66 in early afternoon trading on Friday.

Juno is a clinical-stage biopharmaceutical company that works by developing cellular immunotherapies and medicines that re-engage the body's immune system in order to treat cancer.

TheStreet's Bryan Ashenberg and Bob Lang of Trifecta Stocks have identified Juno Therapeutics as the 'Chart of the Day'. Here is what Ashenberg and Lang had to say:

Juno Therapeutics is one of those new cancer immunotherapy, CAR-T biotech names that has lately been on fire.

(Chimeric antigen receptors, or CARs are proteins that allow the T cells to recognize a specific protein, or antigen, on tumor cells)

The stock shows a very strong uptrend of late, and in impressive fashion, has risen sharply on days the market was down. That is strong Relative Strength, indicated by the action in the top pane. We notice a consolidation from the highs in early April that held above the levels where the stock first started trading in December of 2014 ($38 to $40).

Want more like this from Bryan Ashenberg and Bob Lang BEFORE your stock moves? Learn more about Trifecta Stocks now!

More from Markets

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

FTC Chair Says Agency Is Ready to Take on Big Tech; Walgreens Joins Dow -- ICYMI

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Dow Gets Swept Into Nasty Reversal Even as Nasdaq Posts New Record

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

Zoom CEO Eric Yuan Leads Glassdoor's List of Top 100 CEOs

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

REPLAY: Jim Cramer on Fed Rate Hikes, Oil Prices and Starbucks Worries

3 Must Reads on the Market From TheStreet's Top Columnists

3 Must Reads on the Market From TheStreet's Top Columnists